Pancreatic Cancer Clinical Trial
Official title:
A Randomized Control Trial of Prevena Peel & Place Dressing Versus Standard Closure for Patients Undergoing Pancreaticoduodenectomy Who Have Undergone Neoadjuvant Chemotherapy or Biliary Stent Placement
Pancreaticoduodenectomy is associated with high perioperative morbidity, with surgical site
infection (SSIs) being one of the most common complications. A retrospective study at Hopkins
on SSIs in these patients identified the rate of SSIs to be 16.7% and pre-operative bile
stent/drain and neoadjuvant chemotherapy were independent predictors of surgical site
infection. Patients with these factors having a predicted risk of up to 32%. Another
subsequent retrospective study demonstrated that the use of negative pressure wound therapy
device was significantly associated with a decrease in the rate of SSIs.
The hypothesis of the investigator(s) for the current study is that placement of Prevena Peel
& Place Dressing (Negative Pressure Wound Therapy, NPWT) in patients undergoing
pancreaticoduodenectomy who are at high risk of SSIs will result in a significant decrease in
their SSI rate.
Although outcomes of pancreaticoduodenectomy have improved, it remains a procedure with a
high perioperative complication rate. Surgical site infection is one of the most common
complications after pancreaticoduodenectomy. In a retrospective review of all patients who
underwent pancreaticoduodenectomy at Johns Hopkins between 9/2011 and 8/2014, a total of 679
patients, 30-day surgical site infection was observed in 16.7%. By univariate analysis,
perioperative blood transfusion, operative time greater than 7 hours, preoperative
chemotherapy and/or radiation, bile stent, absence of a superficial wound vacuum closure
device, and vascular resection were associated with surgical site infection (all, p<0.05). On
multivariable analysis, pre-operative bile stent/drain and neoadjuvant chemotherapy were
independent predictors of surgical site infection (all, p<0.001). Studies in colorectal
patients have found an estimated cost of up to $1400 per patient secondary to prolonged
hospitalization, wound care, and wound complications in patients with procedures complicated
by a surgical site infection. Furthermore, in another study of 1144 patients undergoing
pancreaticoduodenectomy between 1995 and 2011 at Johns Hopkins Hospital, post-operative
complications delayed time to adjuvant therapy, decreased median survival.
The hypothesis of the investigator(s) is that placement of Prevena Peel & Place Dressing
using the standard Acelity vacuum dressing after suture on patients undergoing
pancreaticoduodenectomy at highest risk of infection will result in a significant decrease in
surgical site infection rate. The investigator(s) plan to perform a randomized control trial
where the patients who have had pre-operative bile stent/drain placement and/or neoadjuvant
chemotherapy will undergo closure with Prevena Peel & Place Dressing using the standard
Acelity vacuum dressing after suture versus standard closure. The investigator(s) will then
follow the participant(s) for 30 days postoperatively to determine surgical site infection
and other perioperative complication rate.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|